Peptide blends: GLOW, KLOW, Wolverine and CJC-IPA
No blend has been tested in any trial. Evidence exists only for individual components.
At a glance. Four co-lyophilized combinations, each containing compounds that have been studied separately but never together.
Written and maintained by the AVERON Research Desk · Last reviewed September 2026
What these blends are
Each blend below combines two or more compounds in fixed proportions in a single vial. They are co-lyophilized: mixed as a liquid at the factory and freeze-dried together into one uniform powder. AVERON does not mix compounds itself. How blends work in general is explained in peptide blends explained.
The most important thing to know about all four: no trial has ever tested any of these combinations. The evidence for each blend is only the evidence for its individual components, and for most of those components the evidence is animal research.
GLOW — 70 mg
| Component | Amount |
|---|---|
| GHK-Cu | 50 mg |
| BPC-157 | 10 mg |
| TB-500 | 10 mg |
Combines a copper peptide studied topically for skin with the two most widely used repair peptides. GLOW is associated with both skin quality and tissue recovery. The solution is blue because of the copper in GHK-Cu.
Component evidence: GHK-Cu — early human data, topical only · BPC-157 — preclinical only · TB-500 — preclinical only.
KLOW — 80 mg
| Component | Amount |
|---|---|
| GHK-Cu | 50 mg |
| BPC-157 | 10 mg |
| TB-500 | 10 mg |
| KPV | 10 mg |
The GLOW combination with KPV added, a small peptide studied in mice for its anti-inflammatory activity in the gut.
Component evidence: as for GLOW, plus KPV — preclinical only.
Wolverine — 20 mg
| Component | Amount |
|---|---|
| BPC-157 | 10 mg |
| TB-500 | 10 mg |
The two repair peptides together in equal amounts, in one vial instead of two.
Component evidence: BPC-157 — preclinical only · TB-500 — preclinical only.
CJC-IPA — 10 mg
| Component | Amount |
|---|---|
| CJC-1295 without DAC | 5 mg |
| Ipamorelin | 5 mg |
Two compounds that stimulate growth hormone release through different pathways.
Component evidence: CJC-1295 and Ipamorelin — early human data for each compound separately, none for the combination.
How blends are tested
For a blend, independent laboratories report the identity and amount of each component, but not a purity figure. The impurities of several peptides overlap in the analysis and cannot be separated. That is a limit of the method, not a sign of a poor product. See HPLC purity explained.
What it does not do, and what is not known
- None of these combinations has been tested in a human or animal trial as a combination.
- Combining compounds does not add up their evidence. A blend of three preclinical compounds is still preclinical.
- The proportions are fixed. More of one component always means proportionally more of the others.
- Whether the compounds interact with each other in the body is unknown.
- GLOW and KLOW contain copper, which can react with other compounds, so they should never share a vial or cartridge with anything else.
Adverse effects reported in research
There is no safety data for any of these combinations. The individual component pages describe what is and is not known for each.
Anti-doping status
GLOW, KLOW and Wolverine all contain BPC-157, named on WADA's Prohibited List under S0, and TB-500, named under S2.
CJC-IPA contains CJC-1295 and ipamorelin, both named under S2.
All four blends are prohibited at all times in tested sport.
At AVERON
| Blend | Status | Independent lab report |
|---|---|---|
| GLOW 70 mg | In stock | 93199_R74PCJVXZPNI |
| CJC-IPA 10 mg | In stock | 105140_N2WTIRKQ1D9A |
| KLOW 80 mg | Arriving | Published before sale |
| Wolverine 20 mg | Arriving | Published before sale |
Frequently asked questions
Doses mentioned on this page are the arms of published studies, given to describe their results. They are not guidance.

